ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

NaamABBVON

PositieNo.3358

Marktkapitalisatie$0.00

Volledig verwaterde marktkapitalisatie$0.00

Marktaandeel%

Handelsvolume/marktkapitalisatie (24 uur)953,719.31%

Circulerende voorraad125.85328724

Maximale voorraad0

Totale voorraad125.85328724

Circulatiesnelheid%

Uitgiftedatum--

De prijs waartegen het actief voor het eerst werd uitgegeven--

Hoogste prijs ooit237.64005999136555,2026-03-05

Laagste prijs193.3720963640878,2026-04-29

Publieke blockchainETH

InleidingAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Sector

Sociale media

• Officiële website
• Blokverkenner

etfindex:mc_etfindex_sourceDisclaimer: De door cmc verstrekte gegevens mogen niet worden beschouwd als beleggingsadvies.